ErbB3 interacts prominently with the phosphoinositide-3-kinase (PI3K)/AKT pathway, and its overexpression has been reported in many primary cancers, including carcinomas of the stomach, colon, pancreas, oral cavity, breast, ovarian, prostate, and lung ([27]. Here, ERBB3 is linked to gastric carcinoma.